Humanigen HGEN Stock News

Humanigen Inc (OTCMKTS: HGEN) is likely to fly when the opening bell rings this morning, and for good reason. The company announced that it has dosed its first COVID-19 patient in a Phase 3 clinical trial. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

HGEN Stock Is One To Watch On Dosing News

In the press release, Humanigen said that it has dosed its first patient in a Phase 3 clinical trial. In the trial, the comapny is assessing lenzilumab, an anti-human granulocyte macrophage-coloy stimulating factor (GM-CSF) monoclonal antibody. The treatment is being assessed as a potential option to treat patients with COVID-19.

In a statement, Dr. Cameron Durrant, CEO at HGEN, had the following to offer:

We are working with some of the top centers and clinicians in the US, alongside our contract research organization partner, CTI, to advance lenzilumab through Phase III with the intent to prevent serious and potentially fatal outcomes in high risk patients who are hospitalized with COVID-19. We are encouraged by our experiences in the compassionate use patients treated with lenzilumab and look forward to working with stakeholders to share these data.

GM-CSF has been shown to be earlier in the cascade, or ‘upstream’, of multiple other cytokines, such as IL-6, IL-1 and TNF-α in cytokine storm. Excess GM-CSF production is thought to be the key initial trigger in certain disease states that may lead to significant ‘downstream’ consequences, as these and other cytokines become elevated. Therefore, the possibility exists that cytokine storm may be prevented or minimized by neutralizing GM-CSF. As the only company working on prevention of cytokine storm through GM-CSF neutralization for nearly three years, we have multiple accepted publications in this field, substantial safety data, including in patients with severe respiratory disease, and have filed extensive IP. We are grateful to FDA, CTI, other partners and our extensive network of recruitment centers in their support to enable recruitment of patients into this study as quickly as possible.

This News Is Huge!

The news issued by HGEN today is very important. First and foremost, we all know that COVID-19 is a very serious issue. As the world grapples with social distance, riots are starting with consumers wanting to go back to work. Everyone is waiting for economies to open. Everyone wants to be able to go to work, go to the store, send their children to school and more.

However, the only way we’re going to get back to a sense of normal is if we have testing, vaccines, and treatments. While there are plenty of companies working on treatments, Humanigen is far ahead of the vast majority of them.

Not only does the company have a potential treatment option, this treatment is now actively being tested in Phase 3 trials. Should the results of these trials be as positive as results in previous trials of the drug, HGEN may have one of the first treatments to hit the market, and that would be overwhelmingly valuable!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Get Free Alerts

Join our free mailing list to receive stock alerts!

This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Humanigen, CNA Finance has been hired for a period beginning on 3/23/20 and ending on 4/23/20 to conduct digital advertising and marketing and publicly disseminate information about HGEN via Websites and Email. We have an agreement and are currently owed $10,000 by via bank wire transfer to cover the cost of content production. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Humanigen has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.